Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Production / Operations Routine +

VVT Med Announces First Patients Treated with VVT's ScleroSafe(TM) System in Italy

VVT Med Executes European Rollout with First Italian Patient Treatments Following Strong Clinical Validation

By The Northwire Desk — AI Analysis May 26, 2026 · 08:00 TSXV: NaN
Executive Summary
  • The most recent news release dated 2026-05-26 announces the treatment of the first patients in Italy using the ScleroSafe™ System.
  • This milestone occurred at Fondazione Villa Salus Hospital in Mestre, Venice, utilizing a local distributor partnership with Uber Ros S.p.A.
  • The event follows two prior announcements: a clinical data publication on 2026-04-30 showing 100% success rates and a distribution agreement signed on 2026-04-27 securing the Italian market.
  • The ScleroSafe™ System is described as a non-thermal, non-tumescent (NT-NT) solution for venous disease that eliminates thermal energy or tumescent anesthesia requirements.
  • Management quotes emphasize the distinct approach to sclerotherapy and confidence in the European expansion strategy.
Material Impact
  • The news represents execution of previously announced plans rather than a new market-moving catalyst.
  • The April 27 distribution agreement established the framework for this rollout, making the May 26 patient treatment an expected operational milestone.
  • Clinical data published on April 30 provided the necessary evidence base to support commercial adoption in Italy.
  • While positive, the news does not alter the fundamental valuation thesis or introduce new revenue streams beyond what was already committed in the $2.3 million minimum purchase agreement.
  • The impact is incremental validation of the distribution strategy rather than a material shift in company risk profile or growth trajectory.
TSXV: · Price
Company Overview
  • VVT Med Inc. is a medical technology company focused on venous disease treatment solutions.
  • Flagship Project: ScleroSafe™ System, an FDA-cleared and CE-marked catheter-directed sclerotherapy system.
  • Technology Differentiation: Non-thermal, non-tumescent (NT-NT) approach allowing controlled sclerosant delivery with simultaneous blood aspiration.
  • Target Market: Office-based treatment for various vein diameters, specifically symptomatic primary varicose veins.
  • Current Status: Commercializing in North America and expanding into Europe, with Italy being the latest focus market.
Read the original news release →

More from NaN

Jun 11, 2026 · 08:30

VVT Med Advances Global Commercial Rollout of ScleroSafe with Dominican Republic Entry and Tranche 2 Financing

Financings Apr 30, 2026 · 08:30

Clinical Validation and Distribution Expansion Drive Incremental Growth for ScleroSafe Platform

Other Apr 27, 2026 · 09:00

VVT Med Secures Italian Distribution with Investor Participation, Incremental Revenue Stream Established

M&A / Property